Methods and reagents for the rapid and efficient isolation of circulating cancer cells
CA 2432361 C · Owner: Board Of Regents, The University Of Texas System · Inventors: Racila, Emilian V.; Terstappen, Leon W. M. M.; Liberti, Paul A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric and immunocytochemical analysis to detect enumerate and characterize carcinoma cells in the blood. The assay can detect one epithelial cell or less in 1 ml of blood and has a greater sensitively than conventional PCR or immunohistochemistry by 1-2 orders of magnitude. In addition the assay facilitates the biological characterization and staging of carcinoma cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 12, 1999 and granted October 11, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 12, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 12, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.